Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK

Medical Devices: Evidence and Research

Volumn 5, Issue 1, 2012, Pages 39-44

  Marty, Rémi ^b   Roze, Stéphane ^b   Kurth, Hannah ^a  

^a HEVA   (France)

^b IPSEN   (France)

Author keywords

Acromegaly and neuroendocrine tumors; Clogging; Cost savings; Injection

Indexed keywords

ANNUAL SAVINGS; CLOGGING; COST DRIVERS; COST SAVING; DECISION-TREE MODEL; GERMANY; HEALTH CARE PROVIDERS; HEALTH ECONOMICS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PATIENT POPULATION; SIZE ESTIMATION; SOMATOSTATIN RECEPTORS;

FORESTRY; HEALTH RISKS; HOSPITALS; INJECTION (OIL WELLS); LIGANDS; PATIENT TREATMENT; RISK PERCEPTION; TUMORS;

COSTS;

ANGIOPEPTIN; LONG ACTING DRUG; OCTREOTIDE; SANDOSTATINE LAR; SOMATULINE AUTOGEL; UNCLASSIFIED DRUG;

ACROMEGALY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DECISION TREE; DEVICES; DOSE TIME EFFECT RELATION; DRUG COST; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH ECONOMICS; HUMAN; NEUROENDOCRINE TUMOR; POPULATION RESEARCH; RISK REDUCTION; UNITED KINGDOM;

COST ANALYSIS; HEALTH; HOSPITALS; INJECTION; LIGANDS; PLUGGING; RISK ASSESSMENT; TUMORS;

EID: 84860799680     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006; 335:2258-2273.
2. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
3. Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly. Nat Rev Endocrinol. 2011;7:291-300.
4. Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther. 2010;3:169-188.
5. Murray R, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957-2868.
6. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005;153:737-740.
7. Adelman DT, Burgess A, Davies PR. Nurse evaluation of long acting somatostatin analog injection devices: a quantitative study. Presented at the 8th Annual ENETS Conference, Lisbon, Portugal, 9-11 March 2011.
8. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151:317-324.
9. Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4):41-416.
10. Reincke M, Petersenn S, Buchfelder M, et al. The German acromegaly registry: description of the database and initial results. Exp Clin Endocrinol Diabetes. 2006;114:498-505.
11. Jenkins P, Fairclough P. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut. 2002;51(Suppl 5):513-514.
12. IHS Global Insight Pricing & Reimbursement Database, accessed April 21, 2011.
13. Lauer-Taxe 2010 Pharmaceutical Database, accessed April 21, 2011.
14. MIMS Prescription Drug Database, accessed April 21, 2011.
15. European Central Bank. Statistics, Euro foreign exchange reference rates. Available from: http://www.ecb.int/stats/exchange/eurofxref/html/ eurofxref-graph-gbp.en.html. Accessed April 21, 2011.
16. Observatoire des Hommes et des Organisations, Lab'Ho. Health Professionals in Europe. Staffing, training, recognition of occupations, mobility, shortage, remuneration [Les Professionnels de la santé en Europe. Effectives, formations, reconnaissance des professions, mobilité, pénurie, rémunérations]. Available from: http://www.labho.fr/. Accessed April 20, 2011. French.
17. French National Nurses Coordination. Schedule of fees. Available from: http://www.coordination-nationale-infrmiere.org/index.php/Grille-des-salaires. Accessed April 15, 2011.
18. Decree No. 201-2761 of 7 July 2010 on increased pay for military and civilian personnel of the State, local government staff and public hospital [Décret no 2010-2761 du 7 juillet 2010 portant majoration de la rémunération des personnels civils et militaires de l'Etat, des personnels des collectivités territoriales et des établissements publics d'hospitalisation]. Published on JORF no 0156 NOR: MTSX1017587D, July 8, 2010. French. Notes
19. t 2008, applicable since April 18, 2009 and still enforced in 2010. French. Notes
20. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14:284-294.
21. Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004;27:1034-1039.
22. Luque-Ramirez M, Paramo C, da Varela CC, Garcia-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest. 2007;30:541-545.
23. Schweinsberg K, Smith S, Kirshner LS. Ease of administration of somatostatin analogs, octreotide LAR versus lanreotide. Presented at the 93rd annual meeting of the Endocrine Society, June 4-7, 2011, Boston, MA.